Intercell Announces First Subject Enrolled in a Phase II Trial for the further development of its Vaccine Enhancement Patch

Phase II clinical trial investigating the effectiveness of Intercell’s Vaccine Enhancement (VE) Patch in combination with an injectable H5N1 pandemic influenza vaccine

02-Jun-2009 - Austria

Intercell AG announced that it has advanced its efforts to develop its VE Patch to improve prevention of H5N1 pandemic influenza with the start of a Phase II clinical trial. The randomized and blinded study aims to determine the optimal dosage of both Intercell’s VE Patch and the H5N1 influenza vaccine injected concomitantly, when combined with each other in a single dose regimen. The trial will be conducted in the U.S. and is expected to enroll 500 subjects at six study sites.

“The commencement of this Phase II study represents an important milestone in the clinical development of our VE Patch technology and in the partnership with HHS for use of our technology in providing potentially improved Pandemic Influenza vaccines“ stated Thomas Lingelbach, COO of Intercell AG and CEO of Intercell USA. “The recent H1N1 influenza situation certainly highlights again the important global public health need in this arena. If we achieve our goal to achieve full protection with only a single dose plus patch this means an enormous logistical advantage making PanFlu immunization feasible”.

The H5N1 pandemic influenza vaccine tested in the study comprises Intercell’s VE Patch and an injectable H5N1 influenza vaccine manufactured by Solvay Biologicals, B.V. (Netherlands).

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances